Skip to content

Evaluate the Effectiveness and Safety of Variable Frequency Stimulation Compared With Constant Frequency Stimulation for Patients With Idiopathic Parkinson's Disease

Evaluate the Effectiveness and Safety of Variable Frequency Stimulation Compared With Constant Frequency Stimulation for Patients With Idiopathic Parkinson's Disease(RESTEP Study)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03053726
Enrollment
106
Registered
2017-02-15
Start date
2017-08-18
Completion date
2019-12-31
Last updated
2018-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Variable Frequency Stimulation

Brief summary

In the VFS paradigm the stimulation frequency was set to alternate between high and low frequencies, where the frequency of stimulation or frequency combinations can be changed instantaneously according to damage of the moment rhythms. Variable frequency stimulation is a novel dynamic therapy which breaks through the existing single high-frequency stimulation paradigms. It is the world's first VFS therapy for the brain.

Detailed description

In advanced stages of PD, motor symptoms and dyskinesia are effectively treated by deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) . Traditionally, in this procedure, stimulation is set to a constant frequency electrical stimulation with the physician programming the parameters of stimulation frequency, pulse width and amplitude, and stimulated patients' brain nuclei with single frequency, single pulse width and single amplitude of the electric stimulation. Indeed, high frequency stimulation (HFS) of the STN provides consistent, long-term improvement of the cardinal signs of PD . However, the treatment effects of HFS on the axial symptoms of PD, specifically FOG can be poor often causing further impairment. While this can be alleviated by using relatively low frequency stimulation (LFS) , major concerns in the clinical application of LFS exist in regards to its duration of therapeutic benefit. Previous studies have shown that LFS of the STN improves the axial motor signs in some PD patients, but a loss of therapeutic efficacy is seen in the short term. Thereafter, patients may present increased tremor, rigidity and bradykinesia, which is often intolerable outweighing the initial benefits of LFS therapy for FOG. As such, a suitable treatment strategy for FOG remains to be established. Based on previous findings on the relationships between stimulation frequency and movement rhythm regulation in the human body, The National Engineering Laboratory for Neuromodulation, Tsinghua University, proposes a method of variable frequency stimulation (VFS) for aiding movement.

Interventions

PROCEDUREVariable Frequency Stimulation

vary the frequency of the stimulation parameter

Sponsors

Beijing Pins Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Patients and the outcomes assessor are blinded in this study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients With Idiopathic Parkinson's Disease. 2. ≥18 years,both male and female 3. Patients who under deep brain stimulation 4. MMSE score ≥24 5. H-Y≥2.0 under the medicine off/ constant frequency stimulation state 6. The 14 item of UPDRS-II score ≥1 7. The 15 item of UPDRS-II score ≥2 8. Subjects had an ability to walk ≥ 10 meters independently under the medicine off/ constant frequency stimulation state

Exclusion criteria

1. Pregnant women or breastfeeding mothers, or woman who cannot take effective measures to prevent pregnancy. 2. Presence of other diseases affecting walking distance, such as joint disease in lower body, spinal disease, neuropathy, serious heart or lung disease. 3. Diseases seriously affecting health and life, such as tumour, serious liver or kidney diseases etc. 4. Patients with epilepsy etc. 5. Presence of mental disorders or dementia. 6. Patients or their families who cannot comprehend the therapy or patients who are unable to give informed consent voluntarily. 7. Patients whom cannot cooperate well with follow-up requirements. 8. Patients excluded based on the researchers judgement for participation in the clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Stand-Walk-Sitat 3 months compare to baselineThe total time of patients who complete the Stand-Walk-Sit task

Secondary

MeasureTime frame
United Parkinson's Disease Rate Scale scoresat 3、6 months compare to baseline
The39-item Parkinson's Disease Questionnaire (PDQ-39) scoresat 3、6 months compare to baseline
The Freezing of Gait Questionnaire (FOG-Q) scoresat 3、6 months compare to baseline
Gait and Falls Questionnaire (GFQ) scoresat 3、6 months compare to baseline

Countries

China

Contacts

Primary ContactFumin Jia
pins_medical@163.com010-60736388
Backup ContactLuming Li
010-60736388

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026